These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

7623 related items for PubMed ID: 1386286

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro.
    Guilloux Y, Viret C, Gervois N, Le Dréan E, Pandolfino MC, Diez E, Jotereau F.
    Eur J Immunol; 1994 Sep; 24(9):1966-73. PubMed ID: 7522155
    [Abstract] [Full Text] [Related]

  • 3. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
    Itoh K, Platsoucas CD, Balch CM.
    J Exp Med; 1988 Oct 01; 168(4):1419-41. PubMed ID: 3262710
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody.
    Mansfield PF, Rosenblum MG, Murray JL, Itoh K.
    Cancer Immunol Immunother; 1991 Oct 01; 33(4):247-54. PubMed ID: 1829394
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility-complex-negative human tumour: neuroblastoma.
    Facchetti P, Prigione I, Ghiotto F, Tasso P, Garaventa A, Pistoia V.
    Cancer Immunol Immunother; 1996 Mar 01; 42(3):170-8. PubMed ID: 8640845
    [Abstract] [Full Text] [Related]

  • 9. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M.
    Cancer; 1994 Aug 15; 74(4):1275-82. PubMed ID: 7914469
    [Abstract] [Full Text] [Related]

  • 10. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT, Pinto CE, Gifford JD, Kurnick JT, Kradin RL.
    J Immunol; 1989 Nov 15; 143(10):3404-11. PubMed ID: 2509557
    [Abstract] [Full Text] [Related]

  • 11. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
    Hayakawa K, Salmeron MA, Parkinson DR, Markowitz AB, von Eschenbach AC, Legha SS, Balch CM, Ross MI, Augustus LB, Itoh K.
    J Immunother (1991); 1991 Oct 15; 10(5):313-25. PubMed ID: 1790139
    [Abstract] [Full Text] [Related]

  • 12. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
    Tamada K, Harada M, Okamoto T, Takenoyama M, Ito O, Matsuzaki G, Nomoto K.
    Cancer Immunol Immunother; 1995 Dec 15; 41(6):339-47. PubMed ID: 8635191
    [Abstract] [Full Text] [Related]

  • 13. Frequency analysis of lymphokine-secreting CD4+ and CD8+ T cells activated in a graft-versus-host reaction.
    Kelso A.
    J Immunol; 1990 Oct 01; 145(7):2167-76. PubMed ID: 1975827
    [Abstract] [Full Text] [Related]

  • 14. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation.
    Finke JH, Rayman P, Hart L, Alexander JP, Edinger MG, Tubbs RR, Klein E, Tuason L, Bukowski RM.
    J Immunother Emphasis Tumor Immunol; 1994 Feb 01; 15(2):91-104. PubMed ID: 7907918
    [Abstract] [Full Text] [Related]

  • 15. Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.
    Mulder WM, Stukart MJ, Roos M, van Lier RA, Wagstaff J, Scheper RJ, Bloemena E.
    Cancer Immunol Immunother; 1995 Nov 01; 41(5):293-301. PubMed ID: 8536275
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Monoclonal antibodies anti-CD3, anti-TCR alpha beta and anti-CD2 act synergistically with tumor cells to stimulate lymphokine-activated killer cells and tumor-infiltrating lymphocytes to secrete interferon gamma.
    Chong AS, Staren ED, Scuderi P.
    Cancer Immunol Immunother; 1992 Nov 01; 35(5):335-41. PubMed ID: 1382856
    [Abstract] [Full Text] [Related]

  • 18. Differential regulation by interleukin-4 and interferon-gamma of an autologous melanoma-specific cytotoxic T-cell clone and the tumor-infiltrating lymphocytes from which it was established.
    Yamada T, Holmes EC, Golub SH.
    Cancer Commun; 1990 Nov 01; 2(3):113-21. PubMed ID: 2114166
    [Abstract] [Full Text] [Related]

  • 19. Central role for TCR/CD3 ligation in the differentiation of CD4+ T cells toward A Th1 or Th2 functional phenotype.
    Röcken M, Müller KM, Saurat JH, Müller I, Louis JA, Cerottini JC, Hauser C.
    J Immunol; 1992 Jan 01; 148(1):47-54. PubMed ID: 1345789
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 382.